A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer

Launched by ALPHA TAU MEDICAL LTD. · Dec 11, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for patients with advanced pancreatic cancer that cannot be surgically removed, known as unresectable pancreatic cancer. Researchers are testing a device that delivers a special type of radiation directly into the tumor to see if it can help shrink or control the cancer. The trial is currently recruiting participants who are between 18 and 74 years old, have been diagnosed with pancreatic adenocarcinoma, and have already tried at least one round of chemotherapy or are not fit for further chemotherapy.

To join the study, participants need to have a specific type of tumor that can be treated with this radiation device and must be in fairly good health overall. They can expect to receive this new treatment, along with regular follow-ups to monitor their progress and any side effects. It's important for potential participants to know that they will need to use effective birth control methods during and after the study if they are capable of becoming pregnant. This trial aims to provide new hope for patients with this challenging disease by testing an innovative approach to treatment.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Histologically and/or cytologically proven locally advanced or metastatic pancreatic adenocarcinoma
• • Patients must have i) received at least one line of chemotherapy OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery or the patient does not wish to go through surgery
• • Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician
• • Interstitial radiation indication validated by a multidisciplinary team
• • Measurable lesion per RECIST (version 1.1) criteria
• • Lesion size ≤ 5 cm in the longest diameter
• • Age ≥18 years old
• • ECOG Performance Status Scale ≤ 2
• • Life expectancy is more than 6 months
• • WBC ≥ 3500/µl, granulocyte ≥ 1500/µl
• • Platelet count ≥60,000/µl
• • Calculated or measured creatinine clearance ≥ 60cc/min. Calculated or measured creatinine clearance can be≥ 40cc/min given stability of creatinine levels over the past three weeks (at least 1 test per week).
• • AST and ALT ≤ 2.5 X upper limit of normal (ULN)
• • INR \< 1.4 for patients not on Warfarin
• • Subjects are willing and able to sign an informed consent form
• • Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy.
• • Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
• Exclusion Criteria:
• • Concomitant chemotherapy or immunotherapy within the past 4 weeks
• • Brain metastases
• • Borderline unresectable pancreatic cancer, and/or cases fit for surgical exploration unless patient refuses surgery
• • Known hypersensitivity to any of the components of the treatment.
• • Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.
• • Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.
• • Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.
• • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
• • Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.
• • Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
• • Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
• • High probability of protocol non-compliance (in opinion of investigator).
• • Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.